Author

L. Jerby

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:deep learning· 3 Research Focus:differential expression· 3 Research Focus:gene regulatory network inference· 3 Organism:human· 3 Assay:scRNA-seq· 3 Research Focus:cell type annotation· 2 Approach:statistical model· 2 Research Focus:cell-cell communication· 1

Frequent Co-Authors

A. Regev· 2 shared O. Rozenblatt-Rosen· 2 shared A. B. Haynes· 1 shared A. C. Anderson· 1 shared A. Madi· 1 shared A. R. Richman· 1 shared A. Volorio· 1 shared A. Wang· 1 shared

Activity by Year

2019-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

A. Regev

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Mapping ovarian cancer spatial organization uncovers immune evasion drivers at the genetic, cellular, and tissue level

C. Y. Yeh, K. Aguirre, O. Laveroni, S. Kim, A. Wang, B. Liang, X. Zhang, L. M. Han, R. Valbuena, S. K. Plevritis, M. C. Bassik, M. P. Snyder, B. E. Howitt, L. Jerby

This study maps ovarian cancer spatial organization and identifies immune evasion drivers through single-cell spatial transcriptomics and CRISPR screens.

bioRxiv · Oct 16, 2023Cancer Biology

Pan-cancer mapping of single T cell profiles reveals a TCF1:CXCR6-CXCL16 regulatory axis essential for effective anti-tumor immunity

L. Jerby, K. Tooley, G. Escobar, G. Dandekar, A. Madi, E. Goldschmidt, C. Lambden, O. Rozenblatt-Rosen, A. C. Anderson, A. Regev

The paper identifies a TCF1:CXCR6-CXCL16 regulatory axis critical for anti-tumor immunity by analyzing single-cell RNA-seq data from multiple cancers.

bioRxiv · Oct 31, 2021 · PreprintImmunology

Opposing immune and genetic forces shape oncogenic programs in synovial sarcoma

L. Jerby, C. Neftel, M. E. Shore, M. J. McBride, B. Haas, B. Izar, H. R. Weissman, A. Volorio, G. Boulay, L. Cironi, A. R. Richman, L. C. Broye, J. M. Gurski, C. C. Luo, R. Mylvaganam, , A. Regev

The paper profiles synovial sarcoma tumors to show that the SS18-SSX fusion drives oncogenic programs, which are repressed by immune cells and can be targeted with HDAC and CDK4/6 inhibitors.

bioRxiv · Aug 4, 2019 · PreprintCancer Biology